Tempest Therapeutics Q2 EPS $(0.54) Misses $(0.52) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics reported Q2 earnings of $0.54 per share, beating the analyst consensus estimate of $(0.52) by 203.85 percent. This represents a 168.35 percent increase over losses from the same period last year.
August 10, 2023 | 8:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempest Therapeutics reported a significant beat on Q2 earnings, which could positively impact the stock in the short term.
Tempest Therapeutics reported a significant beat on its Q2 earnings, exceeding analyst estimates by 203.85%. This strong performance, which also represents a substantial year-over-year improvement, could drive positive sentiment among investors and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100